Please use this identifier to cite or link to this item:
標題: Characterization of Staphylococcus aureus ATCC8095
金黃葡萄球菌 ATCC8095 之特性描述
作者: 洪敬晟
Hung, Ching-Cheng
關鍵字: Staphylococcus aureus
出版社: 分子生物學研究所
引用: 1. 張嘉茹 (1998) T7 RNA 聚合酶與 13C/15N 同位素標定核甘酸之純化。國立中興大學生物化學研究所,碩士論文。 2. 蘇苡寧、舒竹青 (2009),金黃葡萄球菌 hsdR 基因接受外來 DNA 的影響。J Biomed Lab Sci. Vol 21 No 2. 69. 3. Arvidson S. 2000. Extracellular enzymes, p. 379–385. In V. A. Fischetti, R. P. Novick, J. J. Ferretti, D. A. Portnoy, and J. I. Rood (ed.), Gram-positive pathogens. ASM Press, Washington, D.C 4. Antos JM, Chew GL, Guimaraes CP, Yoder NC, Grotenbreg GM, Popp MW, Ploegh HL. 2009. Site-Specific N- and C-terminal labeling of a single polypeptide using sortases of different specificity. J Am Chem Soc.131:10800-1. 5. Braun L, Dramsi S, Dehoux P, Bierne H, Lindahl G, Cossart P. 1997. InlB: an invasion protein of Listeria monocytogenes with a novel type of surface association. Mol Microbiol. 25:285-94. 6. Balaban N, Rasooly A. 2000. Staphylococcal enterotoxins. Int J Food Microbiol. 61:1–10. 7. Bania J, Dabrowska A, Korzekwa K, Zarczynska A, Bystron J, Chrzanowska J., Molenda J. 2006. The profiles of enterotoxin genes in Staphylococcus aureus from nasal carriers. Lett Appl Microbiol. 42: 315–320. 8. Buist G, Ridder AN, Kok J, Kuipers OP. 2006. Different subcellular locations of secretome components of Gram-positive bacteria. Microbiology. 152:2867-74. 9. Bubeck Wardenburg J, Schneewind O. 2008. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 205:287–294. 10. Cucarella C, Solano C, Valle J, Amorena B, Lasa L, Penade’s JR. 2001. Bap, a Staphylococcus aureus surface protein involved in biofilm formation. J Bacteriol. 183:2888–2896. 11. Cossart P, Jonquieres R. 2000. Sortase, a universal target for therapeutic agents against gram-positive bacteria? Proc Natl Acad Sci U S A. 97:5013-5. 12. Corvaglia AR, Francois P, Hernandez D, Perron K, Linder P, Schrenzel J. 2010. A type III-like restriction endonuclease functions as a major barrier to horizontal gene transfer in clinical Staphylococcus aureus strains. Proc Natl Acad Sci USA. 107:11954-8. 13. Dinges MM, Orwin PM, Schlievert PM. 2000. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev. 3:16-34. 14. de Kievit TR, Iglewski BH. 2000. Bacterial Quorum Sensing in Pathogenic Relationships. Infect Immun. 68:4839-49. 15. Fattom A, Fuller S, Propst M, Winston S, Muenz L, He D, Naso R, Horwith G. 2004. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. Vaccine 23:656–663. 16. Goodyear CS, Silverman GJ. 2004. Staphylococcal toxin induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. Proc. Natl. Acad. Sci. USA. 101:11392–11397. 17. Gomez MI, O''Seaghdha M, Magargee M, Foster TJ, Prince AS. 2006. Staphylococcus aureus protein A activates TNFR1 signaling through conserved IgG binding domains. J Biol Chem. 281:20190-6. 18. Glowalla E, Tosetti B, Kronke M, Krut O. 2009. Proteomics-based identification of anchorless cell wall proteins as vaccine candidates against Staphylococcus aureus. Infect Immun. 77:2719-29. 19. Holtje JV, Tomasz A. 1975. Specific recognition of choline residues in the cell wall teichoic acid by the N-acetylmuramyl-L-alanine amidase of Pneumococcus. J Biol Chem. 250:6072-6. 20. Hsu CA, Lin WR, Li JC, Liu YL, Tseng YT, Chang CM, Lee YS, Yang CY. 2008. Immunoproteomic identification of the hypothetical protein NMB1468 as a novel lipoprotein ubiquitous in Neisseria meningitidis with vaccine potential. Proteomics. 8:2115-25. 21. Hendrickx AP, Budzik JM, Oh SY, Schneewind O. 2011. Architects at the bacterial surface-sortases and the assembly of pili with isopeptide bonds. Nature Reviews Microbiology. 9:166-76. 22. Jevons MP. 1961. ‘Celbenin’-resistant staphylococci. BMJ. 1:124–125. 23. Kirby WM. 1944. Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science. 99:452-3. 24. Kocks C, Gouin E, Tabouret M, Berche P, Ohayon H, Cossart P. 1992. L. monocytogenes-induced actin assembly requires the actA gene product, a surface protein. Cell. 68:521-31. 25. Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O. 2010. Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J Exp Med. 207:1863-70. 26. Karlsson A, Saravia-Otten P, Tegmark K, Morfeldt E, Arvidson S. 2001. Decreased Amounts of Cell Wall-Associated Protein A and Fibronectin-Binding Proteins in Staphylococcus aureus sarA Mutants due to Up-Regulation of Extracellular Proteases. Infect Immun. 69:4742-8. 27. Kim HK, Kim HY, Schneewind O, Missiakas D. 2011. Identifying protective antigens of Staphylococcus aureus, a pathogen that suppresses host immune responses. FASEB J. 25:3605-12. 28. Loir Y, Baron F, Gautier M. 2003. Staphylococcus aureus and food poisoning. Genet Mol Res. 2:63-76. 29. Lowy FD. 2003. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest. 111: 1265–1273. 30. Lucero CA, Hageman J, Zell ER, Bulens S, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Schaffner W, Fridkin SK; Active Bacterial Core surveillance MRSA Investigators. 2009. Evaluating the potential public health impact of a Staphylococcus aureus vaccine through use of population-based surveillance for invasive methicillin-resistant S. aureus disease in the United States. Vaccine. 27:5061-8. 31. McGavin MJ, Zahradka C, Kelly R, Scott JE. 1997. Modification of the Staphylococcus aureus fibronectin binding phenotype by V8 protease. Infect. Immun. 65:2621–2628. 32. Mazmanian SK, Liu G, Ton-That H, Schneewind O. 1999. Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science. 285:760-3. 33. Mazmanian SK, Liu G, Jensen ER, Lenoy E, Schneewind O. 2000. Sortase, a universal target for therapeutic agents against Gram-positive bacteria? Proc. Natl. Acad. Sci. USA 97:5510–5515. 34. Mazmanian SK, Ton-That H, Su K, Schneewind O. 2002. An iron-regulated sortase anchors a class of surface protein during Staphylococcus aureus pathogenesis. Proc. Natl. Acad. Sci. USA 99:2293-8. 35. McKenney D, Pouliot KL, Wang Y, Murthy V, Ulrich M, Doring G, Lee JC, Goldmann DA, and Pier GB. 1999. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 284: 1523–1527 36. Woodford N. 2005. Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci. Clin Microbiol Infect. 11(suppl 3): 2–21. 37. Maria do Carmo de Freire Bastos, Bruna Goncalves Coutinho and Marcus Livio Varella Coelho. 2010. Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications. Pharmaceuticals. 3:1139-1161. 38. McCallum N, Hinds J, Ender M, Berger-Bachi B, Stutzmann Meier P. 2010. Transcriptional profiling of XdrA, a new regulator of spa transcription in Staphylococcus aureus. J Bacteriol. 192:5151-64. 39. Navarre WW, Schneewind O. 1999. Surface Proteins of Gram-Positive Bacteria and Mechanisms of Their Targeting to the Cell Wall Envelope. Microbiol. Mol. Biol. Rev. 63:174–229. 40. Navarre WW, Daefler S, Schneewind O. 1996. Cell wall sorting of lipoproteins in Staphylococcus aureus. J Bacteriol. 178:441-6. 41. Nakano M, Kawano Y, Kawagish M, Hasegawa T, Iinuma Y, Oht M. 2002. Two-dimensional analysis of exoproteins of methicillin-resistant Staphylococcus aureus (MRSA) for possible epidemiological applications. Microbiol Immunol. 46:11-22. 42. Ohlsen K, Koller K-P, Hacker J. 1997. Analysis of expression of the alpha-toxin gene (hla) of Staphylococcus aureus by using a chromosomally encoded hla:lacZ gene fusion. Infect Immun. 65: 3606–3614. 43. Omoe K, Ishikawa M, Shimoda Y, Hu DL, Ueda S, Shinagawa K. 2002. Detection of seg, seh, and sei genes in Staphylococcus aureus isolates and determination of the enterotoxin productivities of S. aureus isolates harboring seg, seh, or sei genes. J Clin Microbiol. 40: 857–862. 44. O''Neill E, Pozzi C, Houston P, Humphreys H, Robinson DA, Loughman A, Foster TJ, O''Gara JP. 2008. A novel Staphylococcus aureus biofilm phenotype mediated by the fibronectin-binding proteins, FnBPA and FnBPB. J Bacteriol. 190:3835-50. 45. Otto M. 2010. Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin Biol Ther. 10:1049-59. 46. Patti JM. 2004. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine. 22 Suppl 1:S39-43. 47. Pocsfalvi G, Cacace G, Cuccurullo M, Serluca G, Sorrentino A, Schlosser G, Blaiotta G, Malorni A. 2008. Proteomic analysis of exoproteins expressed by enterotoxigenic Staphylococcus aureus strains. Proteomics. 8: 2462–2476. 48. Qiu J, Feng H, Xiang H, Wang D, Xia L, Jiang Y, Song K, Lu J, Yu L, Deng X. 2010. Influence of subinhibitory concentrations of licochalcone A on the secretion of enterotoxins A and B by Staphylococcus aureus. FEMS Microbiol Lett. 307:135-41. 49. Roche FM, Massey R, Peacock SJ, Day NP, Visai L, Speziale P, Lam A, Pallen M, Foster TJ. 2003. Characterization of novel LPXTG-containing proteins of Staphylococcus aureus identified from genome sequences. Microbiology. 149:643-54. 50. Sussenbach JS, Steenbergh PH, Rost JA, van Leeuwen WJ, van Embden JD. 1978. A second site-specific restriction endonuclease from Staphylococcus aureus. Nucleic Acids Res. 5:1153-63. 51. Sompolinsky D, Samra Z, Karakawa WW, Vann WF, Schneerson R, Malik Z. 1985. Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types. J Clin Microbiol. 22:828-34. 52. Silverman GJ, Goodyear CS. 2006. Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat. Rev. Immunol. 6:465– 475. 53. Schito GC. 2006. The importance of the development of antibiotic resistance in Staphylococcus aureus. Clin Microbiol Infect. 12 (Suppl. 1):3-8. 54. Stranger-Jones YK, Bae T, Schneewind O. 2006. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 103:16942–16947. 55. Sakamoto T, Sawamoto S, Tanaka T, Fukuda H, Kondo A. 2010. Enzyme- Mediated Site-Specific Antibody-Protein Modification Using a ZZ Domain as a Linker. Bioconjug Chem. 221:2227-33. 56. Tseng CW, Stewart GC. 2005. Rot repression of enterotoxin B expression in Staphylococcus aureus. J Bacteriol. 187: 5301–5309. 57. Vytvytska O, Nagy E, Bluggel M, Meyer HE, Kurzbauer R, Huber LA, Klade CS. 2002. Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics. 2:580-90. 58. Waldron DE, Lindsay JA. 2006. Sau1: a novel lineage-specific type I restriction- modification system that blocks horizontal gene transfer into Staphylococcus aureus and between S. aureus isolates of different lineages. J Bacteriol. 188:5578-85. 59. Yung SC, Parenti D, Murphy PM. 2011. Host chemokines bind to Staphylococcus aureus and stimulate protein A release. J Biol Chem. 286:5069-77.
摘要: 金黃色葡萄球菌為一伺機性病原菌,會分泌許多種具超級抗原 ( superantigenic )特性的毒素,同時也會導致廣範圍的疾病,例如:食物中毒、肺炎、心內膜炎或敗血症等。過去的研究大多專注於臨床分離的菌株,首先為了瞭解 SA 適應不同環境的生理生態特徵,本研究使用 SDS-PAGE 針對分離自奶油派的 ATCC8095 及臨床分離的 SA 菌株,分析其胞外蛋白質圖譜。在 ATCC8095 中發現一蛋白質條帶在 55 kDa 較其它菌株明顯,此蛋白質條帶經由質譜儀及西方墨點法分析確認為 Staphylococcal protein A (Spa),接著分析 ATCC8095 及臨床分離株 (TC1057) 其 Spa 蛋白質在不同時間表現情形。ATCC8095 菌體相關連之 Spa 蛋白質,在對數期 (log phase) 開始增加而穩定期 (stationary phase) 逐漸減少;直至後穩定期 (post-exponential phase) 幾乎偵測不到,胞外的 Spa 蛋白質則可穩定的增加至後對數期,相對地, TC1057 菌體相關連之 Spa 蛋白質在穩定期仍維持著高表現量。已知 Spa 蛋白質會因 sortase (SrtA) 的作用,經由其 LPXTG motif 鑲嵌至細胞壁中,由 spa 及 srtA 的序列分析,顯示 ATCC8095 之 spa 所表現的蛋白質帶有典型的LPXTG 鑲嵌 motif ,但是其 srtA 基因在第96個密碼子具有一個無意義突變(nonsense mutation),產生了一個截斷的(truncated)蛋白質,此 srtA 的無意義突變或許是造成 ATCC8095 之胞外最大量蛋白質為 Spa 的原因,而此推測經由比較 RN4220 及其 srtA 突變株之 Spa 蛋白表現圖譜可獲得驗證。在上述的研究過程中,發現srtA 突變株與野生株相較之下,突變株之胞外 Spa 對 IgG 展現較低的結合能力,野生株其胞外 Spa 經由 pentaglycine 專一性的蛋白內切酶 lysostaphin 處理後,大幅降低其 IgG 結合能力,此結果指出 Spa 其 C 端與肽聚醣(peptidoglycan)的連結,使 Spa 具有較高的 IgG 結合能力。最近已發現 srtA 的突變會造成毒性下降,且可以誘發具保護性的免疫反應,而無論是 Spa 之 IgG 結合能力下降導致的毒性下降,或者可以誘發出具保護力的免疫反應,都值得進一步的研究。
Staphylococcus aureus (SA), an opportunistic pathogen capable of secreting multiple toxins with superantigenic activities, causes a wide spectrum of serious diseases including food poisoning, pneumonia, and septicemia. Studies have been focused mostly on clinical isolates. As an initial effort to investigate the ecophysiological traits associated to SA adaption to different environments, this study analyzed the extracellular protein profiles of the the SA strain ATCC8095 isolated from cream pie and clinical isolates by SDS-PAGE. A protein band around 55 kDa was found distinctly in ATCC8095 but not others. This protein was confirmed to be the Staphylococcal protein A (Spa) by mass spectrometry and Western blotting. Next, the temporal and spatial distributions of Spa protein in ATCC8095 and in one clinical isolate (TC1057) were examed. In strain ATCC8095, the cell-associated Spa levels increased during log phase but diminished gradually in stationary phase, and barely detectable in post-stationary phase, while the extracellular Spa steady increased to post-stationary phase. In contrast, the levels of cell-associated Spa in TC1057 maintained at the highest level in the stationary phase. It is known that Spa protein is anchored to the cell wall via the LPXTG motif and this process is catalyzed by the sortase A (SrtA). Sequence analysis of the spa and srtA genes revealed that the spa gene of ATCC8095 encodes a protein with typical LPXTG anchorage motif but the srtA gene has a nonsense mutation at codon 96 resulting in a truncated protein. The results indicate that a nonsense mutation in SrtA might responsible for the observation that Spa protein is the most abundant extracellular protein in ATCC8095. This speculation is confirmed by comparing the Spa expression patterns between the wild type and the srtA knockout RN4220 strains. In the course of the above studies, it was noted that the extracellular Spa (eSpa) protein of the srtA mutant strains exhibit lower IgG binding activities than that of wild type strains. The IgG binding activity of the eSpa from the wild type strain was reduced after treating with pentaglycine specific endopeptidase lysostaphin. This result indicates that the linking of the C-terminus of Spa to the peptidoglycan renders Spa higher affinity to IgG. Recently, a srtA mutant has been shown to be attenuated and can induce protective immunity. Whether the reduction of IgG binding activity of Spa contributing to the attenuation of virulence and induction of protective immune response were deserved further to investigate.
其他識別: U0005-0602201216242400
Appears in Collections:分子生物學研究所



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.